Diligence memo · auto-generated · as of July 2, 2026
vTv Therapeutics Inc.
vTv Therapeutics Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
vTv Therapeutics Inc. operates in Pharmaceuticals, based in HIGH POINT.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
vTv Therapeutics Inc. has raised $80M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $51M on 2024-02-27.
Most recent recorded round closed around 2024-02-27.
Valuation (modeled)modeled
Provath models vTv Therapeutics Inc. at approximately $502M (range $166M–$800M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.87× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era. Within the normal band (87% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 2.3 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 25.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 88% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
21 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.